Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POCKET-OAC: Pill-in-the-POCKET Anticoagulation After AF Catheter Ablation
NCT06216769Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Composite of ischemic stroke, transient ischemic attack, other systemic embolism, bleeding (major, clinically relevant), all-cause death at 24 months. Started Feb 2024; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06216769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216769.